Skip to main content
Premium Trial:

Request an Annual Quote

Helicos Seeks to Raise $6.4M in Direct Offering

NEW YORK (GenomeWeb News) – Helicos BioSciences said after the close of the market yesterday that it has priced a registered direct offering of 6.4 million units at $1 per unit, which would provide the firm with $6.4 million in gross proceeds.

Each unit in the offering consists of one share of Helicos common stock and a warrant to buy .65 of a share of common stock. The warrants are exercisable for a period of five years beginning six months after issuance, at an exercise price of $1.4385 per share.

Helicos expects to close the offering on or around Dec. 21.

The firm plans to use the proceeds for its ongoing research and development efforts and general corporate purposes.

Helicos filed a registration statement with the US Securities and Exchange Commission in early November, in which it said that it may offer up to $50 million worth of its common stock and/or warrants to purchase common stock in one or more transactions.

In early Wednesday trade on the Nasdaq, shares of Helicos tumbled 30 percent to $.96.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more